Personalizing Self-management in Diabetes - Pilot Study

March 27, 2023 updated by: Olena Mamykina, PhD, Columbia University

Dynamically Tailoring Interventions for Problem-Solving in Diabetes Self-Management Using Self-Monitoring Data

The goal of this study is to conduct a pilot feasibility study a novel informatics intervention, GlucoType (also called Platano for Latino users) that incorporates computational analysis of self-monitoring data to help individuals with type 2 diabetes personalize diabetes self-management strategies. This study will include 20 individuals with type 2 diabetes mellitus (T2DM) recruited from economically disadvantaged and medically underserved communities to test Platano for 4 weeks to assess its acceptability and feasibility. The main outcome measures include problem-solving abilities in diabetes (Diabetes Problem-Solving Inventory (DPSA)) and self-reported diabetes self-care (Summary of Diabetes Self-Care Activities Questionnaire (SDSCA)). In addition, this study will include a controlled laboratory experiment to assess whether participants can understand and follow personalized nutritional goals generated by Platano.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Growing evidence highlights significant differences in individuals' physiology and glycemic function and their cultural, social, and economical circumstances that impact diabetes self-management. These discoveries paved the way for precision medicine-an approach to personalizing medical treatment to an individual's genetic makeup, clinical history, and lifestyle. Computational learning methods have been successfully used for identifying clinical phenotypes-observable manifestations of diseases. Studies showed the benefits of tailoring not only medical treatment, but also behavioral interventions; however, tailoring typically relies on expert identification of tailoring variables and decision rules, and on standard surveys. Data collected with self-monitoring can more accurately reflect an individual's behaviors and glycemic patterns, thus highlighting their "behavioral phenotypes", yet such data are rarely utilized in tailoring.

The ongoing focus of this research is on facilitating problem-solving in diabetes self-management. Well-developed problem-solving skills are essential to diabetes management result in better diabetes self-care behaviors lead to improvements in clinical outcomes and can be fostered with face-to-face interventions. Previous research suggested problem identification and generation of alternatives as critical steps in problem-solving in diabetes. In previous work, the investigators developed an informatics intervention that relied on expert-generated knowledge for assisting individuals on these steps of problem-solving. In this pilot feasibility study, the investigators study an alternative solution that relies on computational pattern analysis of data collected with self-monitoring technologies to tailor the problem-solving assistance to individuals' unique behavioral phenotypes. The intervention, GlucoType uses computational learning methods to identify systematic patterns in individuals' diet, physical activity, and sleep, captured with custom-built and commercial self-monitoring technologies, and correlates these patterns with fluctuations in individuals' blood glucose levels. GlucoType then uses this information to 1) identify behavioral patterns associated with high glycemic excursion, 2) formulate personalized goals to modify these behaviors, 3) provide in-the-moment decision support to help individuals be more consistent in meeting their goals.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10032
        • Columbia University Medical Center
      • New York, New York, United States, 10018
        • Clinical Directors Network

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18-65 years
  • A diagnosis of Type 2 Diabetes.
  • A participant of the Washington Heights/Inwood Informatics Infrastructure for Comparative Effectiveness Research (WICER), a patient of the AIM clinic, or a patient of a participating Federally Qualified Health Center (FQHC) health center for at least 6 months
  • Has participated in at least one diabetes education session at the participating site in the last 6 months
  • Proficient in either English or Spanish
  • Must own a basic cell phone

Exclusion Criteria:

  • Pregnancy
  • Presence of serious illness (e.g. cancer diagnosis with active treatment, advanced stage heart failure, multiple sclerosis)
  • Presence of cognitive impairment
  • Plans for leaving their healthcare provider in the next 12 months
  • Does not have a computer and/or Internet access

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Single arm
Intervention: GlucoType Single arm study; all participants assigned to use the intervention
GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in score on Summary of Diabetes Self-Care Activities Questionnaire (SDSCA)
Time Frame: From Baseline to 4 weeks
Change in score on Summary of Diabetes Self-Care Activities Questionnaire (SDSCA) - 12-item with 5 sub-scales (diet, exercise, home blood glucose testing, foot care, smoking status). The respondent is asked how many days in the past week he/she performed the behavior (ranges from 0 to 7); higher scores indicates higher performance.
From Baseline to 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Olena Mamykina, Ph.D., Columbia University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2018

Primary Completion (Actual)

April 30, 2018

Study Completion (Actual)

April 30, 2018

Study Registration Dates

First Submitted

December 5, 2018

First Submitted That Met QC Criteria

February 15, 2021

First Posted (Actual)

February 17, 2021

Study Record Updates

Last Update Posted (Actual)

March 29, 2023

Last Update Submitted That Met QC Criteria

March 27, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • AAAM0057(a)
  • R56DK113189 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Type 2 Diabetes Mellitus

3
Subscribe